Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $169
Mizuho Securities Remains a Buy on Biogen (BIIB)
Mizuho Cuts Price Target on Biogen to $169 From $207
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $175
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $175
BTIG Maintains Biogen(BIIB.US) With Hold Rating
Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)
Analysts' Opinions Are Mixed on These Healthcare Stocks: OKYO Pharma Limited Sponsored ADR (OKYO), Biogen (BIIB) and Cigna (CI)
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $121 to $255
Biogen Is Maintained at Buy by Canaccord Genuity
Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265
HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $144 to $220
Baird Maintains Outperform on Biogen, Lowers Price Target to $255
Biogen Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Achieve Life Sciences (ACHV)
Research Alert: Biib Reports Q1 Results: Top- And Bottom-line Beat, 2025 Guidance Disappoints
Biogen: Balanced Outlook With Hold Rating Amid Mixed Financial Signals
Biogen's Strong Q1 Performance and Strategic Focus Justify Buy Rating